Solid Phase Antibody Screening
The antibodies directed to the possible donor or an already transplanted organ are known as Donor Specific Antibodies (DSA). These DSA are associated with an increased risk of graft loss and/or rejection. The damage produced by the recognition of the HLA antigens on the surface of the graft endothelium by the DSA result in the rejection process known as Antibody Mediated Rejection (AMR).
The high specificity and sensitivity of the current solid phase single antigen assay allow us the detection of low-level of the precise DSA. The detection of DSA in pre-transplant evaluation is an excellent tool for risk assessment and crossmatch prediction (Virtual Crossmatch and CPRA). The routine monitoring of DSA in the post-transplant setting assist the transplant team in the characterization of the rejection process and the treatment decisions.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
STAT: 48 hours; Routine: 5 days
- HLA Antibody Specificity Class II
- HLA Antibody Specificity Class I
- HLA REPORT
- TISSUE TYPING
- Donor Specific Ab Testing
- Donor Specific Antibody (DSA)
- Class I & II SAB Antibody Screening